IFNγ production by CD8+ T cells after etanercept treatment
| IFNγ/TNFα positive CD8+ T cells (%) | ||
|---|---|---|
| IFNγ | TNFα | |
| Percentage of cytokine positive cells among the CD8+ T cell subpopulation upon in vitro stimulation with the overlapping peptides derived from the G1 domain of aggrecan: median (25th–75th centiles). | ||
| *p<0.05, compared with the value before treatment. | ||
| Etanercept group | ||
| Before treatment | 0.13 (0.02–0.21) | 0.17 (0.03–0.46) |
| After etanercept treatment (6 weeks) | 0.22 (0.06–0.29)* | 0.24 (0.04–0.49) |
| After etanercept treatment (12 weeks) | 0.23 (0.04–0.37)* | 0.19 (0.04–0.3) |
| Placebo group | ||
| Before treatment | 0.19 (0.05–0.35) | 0.14 (0.04–0.3) |
| After placebo treatment (6 weeks) | 0.2 (0.03–0.38) | 0.18 (0.03–0.22) |
| After etanercept treatment (6 weeks) | 0.25 (0.04–0.48)* | 0.23 (0.07–0.38) |